Epigenetic mechanisms work in concert to control transcriptional activity by altering the chromatin landscape of cells. Until recently, enzymatic modulators of writer and eraser classes have been the main focus of therapeutic development. Operating at the interface of translating histone marks, reader domains that recognize the histone code written in acetyl and methyl marks have now emerged as viable targets for therapeutic development. In particular, the BET bromodomain family of readers has gained significant attention for the treatment of human cancers, with several inhibitors developed and clinical-stage programs now underway. Adding to the collection of the already robust targets in reader, writer and eraser classes, strategies are now emerging to regulate gene activity by targeting components of remodelers such as the mammalian SWI/SNF chromatin remodeling complex - which displays functional mutations in several human cancers. In total, chromatin-associated proteins and readers represent significant opportunities for therapeutic intervention far beyond previously imagined.
Cambridge Healthtech Institute's Second Annual Targeting Epigenetic Readers and Chromatin Remodelers meeting will unite academic and industry researchers for the development of chemical probes, and clinical-stage inhibitors to further our understanding of the therapeutic opportunities associated with targeting reader domains and chromatin remodelers.
Who should attend: Directors, Managers, Researchers, and Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Oncology Drug Discovery, Research and Development, Molecular/Cell Biology, Biochemistry, Chemical Genomics/Biology, Structural Biology, Medicinal Chemistry, Pharmacology and Synthetic Chemistry.
Topics may include, but are not limited to:
- Novel Reader Targets with Therapeutic Implications in Cancer and Inflammation
- Novel Chromatin Remodeling Targets with Therapeutic Implications in Cancer and Inflammation
Discovery to Lead
- Targeting Chromatin Remodeling Complexes, BET bromodomains, PhD, Tudor, Chromo, PWWP and MBT domains
- Structural Characterization of Reader Domains and Remodeler Subunits
- High-Throughput Profiling and Screening for Inhibitors
- Virtual Screening
- Phenotypic Screening
- Fragment/Structure-Based Design
- Protein-Protein Interaction Strategies
- Development of High-Quality Chemical Probes/Scaffolds
- Discovery of Novel Inhibitors
- Molecular Mechanism of Action
- Lead Optimization
Preclinical and Clinical Development
- Updates on BET Bromodomain programs in Preclinical and Clinical Stages
- PK/PD - in vitro and in vivo Target Binding Kinetics
- In Vitro Pharmacology
- In Silico Models for Predictive Toxicology
- Disease Relevant Preclinical Models and Biomarkers
If you are interested in speaking, please click here to submit a proposal.
The deadline for submission is March 28, 2014.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the meeting, please contact:
Cambridge Healthtech Institute
T: (+1) 781-972-5454
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483